IDUN: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI) (IDUN)

Principal Investigator

Dr Muhammad Kassim Javaid

Contact us

Email: emcrf@ouh.nhs.uk

IRAS number

1012871